MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ejhf.3742

Медицинская библиотека · European journal of heart failure · 2025

Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes.

Karakas Mahir, Friede Tim, Butler Javed, Talha Khawaja M, Placzek Marius, Asendorf Thomas, Diek Monika, Nosko Anna, Stas Adriane, Kluge Stefan, Jarczak Dominik, DeHeer Geraldine, Rybczynski Meike, Bayes-Genis Antoni, Böhm Michael, Coats Andrew J S, Edelmann Frank, Filippatos Gerasimos, Hasenfuß Gerd, Haverkamp Wilhelm, Lainscak Mitja, Landmesser Ulf, Macdougall Iain C, Merkely Bela, Pieske Burkert M, Pinto Fausto J, Rassaf Tienush, Visser-Rogers Jennifer K, Rosano Giuseppe, Volterrani Maurizio, von Haehling Stephan, Anker Markus S, Doehner Wolfram, Ince Hüseyin, Koehler Friedrich, Savarese Gianluigi, Khan Muhammad Shahzeb, Kröhnert Ursula Rauch, Gori Tommaso, Trenkwalder Teresa, Akin Ibrahim, Paitazoglou Christina, Kobielusz-Gembala Iwona, Kuthi Luca, Frey Norbert, Licka Manuela, Kääb Stefan, Laugwitz Karl-Ludwig, Ponikowski Piotr, Anker Stefan D

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

AIMS: Intravenous iron has emerged as a guideline-recommended therapy in patients with heart failure and iron deficiency, but the potential sex-related differences in efficacy are unknown. We aimed to assess sex-specific outcomes in the Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality (FAIR-HF2-DZHK05) trial.

METHODS AND

RESULTS

FAIR-HF2 included 1105 heart failure patients with a left ventricular ejection fraction ≤45% and iron deficiency. A total of 368 women (mean age 68.7 ± 13.0 years) and 737 men (mean age 70.5 ± 11.0 years) were randomized to intravenous ferric carboxymaltose or placebo. The three primary endpoints were (i) time to cardiovascular death or first heart failure hospitalization, (ii) total heart failure hospitalizations, and (iii) time-to-first event of cardiovascular death or heart failure hospitalization only in patients with transferrin saturation <20% at baseline. The hazard ratio (HR) for the first primary outcome was 1.07 (95% confidence interval [CI] 0.63-1.82, p = 0.80) in women and 0.74 (95% CI 0.57-0.95, p = 0.016) in men, while the rate ratios (RRs) for the second primary outcome were 1.06 (95% CI 0.55-2.05, p = 0.86) and 0.79 (95% CI 0.58-1.08, p = 0.136), respectively, and the HRs for the third primary outcome event were 1.21 (95% CI 0.62-2.36, p = 0.58) and 0.73 (95% CI 0.55-0.97, p = 0.028), respectively. Regarding safety outcomes, the HR for all-cause mortality was 1.46 (95% CI 0.78-2.76, p = 0.24) in women, suggesting increased mortality risk under iron supplementation, in contrast to 0.86 (95% CI 0.64-1.16, p = 0.33) in men (p for interaction = 0.13).

CONCLUSIONS

This analysis indicates relevant differential efficacy of intravenous iron in heart failure across both sexes. While men receiving ferric carboxymaltose experienced a clinically relevant reduction in cardiovascular death and heart failure hospitalizations, women did not derive similar benefits. The results are clinically relevant and prompt validation in other large outcome trials of intravenous iron supplementation in heart failure.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03036462.

Для цитирования: Karakas Mahir, Friede Tim, Butler Javed, Talha Khawaja M, Placzek Marius, Asendorf Thomas, Diek Monika, Nosko Anna, Stas Adriane, Kluge Stefan, Jarczak Dominik, DeHeer Geraldine, Rybczynski Meike, Bayes-Genis Antoni, Böhm Michael, Coats Andrew J S, Edelmann Frank, Filippatos Gerasimos, Hasenfuß Gerd, Haverkamp Wilhelm, Lainscak Mitja, Landmesser Ulf, Macdougall Iain C, Merkely Bela, Pieske Burkert M, Pinto Fausto J, Rassaf Tienush, Visser-Rogers Jennifer K, Rosano Giuseppe, Volterrani Maurizio, von Haehling Stephan, Anker Markus S, Doehner Wolfram, Ince Hüseyin, Koehler Friedrich, Savarese Gianluigi, Khan Muhammad Shahzeb, Kröhnert Ursula Rauch, Gori Tommaso, Trenkwalder Teresa, Akin Ibrahim, Paitazoglou Christina, Kobielusz-Gembala Iwona, Kuthi Luca, Frey Norbert, Licka Manuela, Kääb Stefan, Laugwitz Karl-Ludwig, Ponikowski Piotr, Anker Stefan D. Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes.. European journal of heart failure. 2025. DOI: 10.1002/ejhf.3742.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.